Company Update: Actavis plc (NYSE:ACT) – Actavis cannot drop old version of Alzheimer’s drug – appeals court

[Reuters] – Actavis Plc cannot pull its top-selling Alzheimer’s drug from the market in favor of a pricier extended-release version, a federal appeals court ruled on Friday. The decision is a win for . . . → Read More: Company Update: Actavis plc (NYSE:ACT) – Actavis cannot drop old version of Alzheimer’s drug – appeals court Similar Articles: Stock Update (NYSE:ACT): Actavis Reports Exceptional Performance in First Quarter 2015 with 59% Increase in Net Revenue to $4.2 Billion and 23% Growth in Non-GAAP EPS to $4.30 Company Update: Actavis plc (NYSE:ACT) – U.S. court weighs whether to let Actavis drop Alzheimer’s drug Company Update (NYSE:ACT): (OFFICIAL)-UPDATE 1-Actavis’ superbug antibiotic gets U.S. approval (Feb. 25)